NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR PUBLICATION, PUBLICATION, DISTRIBUTION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
VANCOUVER, British Columbia, February 17, 2023 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. DRUG DRUG (“bright minds” or the “Pursue‘), a biotechnology company focused on developing novel drugs to target neuropsychiatric disorders, epilepsy and pain, today announced its appointment to its board of directors (the ‘plank“) by David Weiner, MD, as Non-Executive Director. The appointment is effective immediately.
“I am delighted to welcome David to the Bright Minds Board of Directors. He is an accomplished neuroscientist and biotech entrepreneur who brings extensive experience in the field of psychedelics. The breadth of his work with 5-HT2A Compounds is ideally suited to support the further development of our next-generation programs. David holds multiple patents in the area of selective serotonin modulators and we look forward to his contributions to the company,” said Ian McDonald, CEO and co-founder of Bright Minds Biosciences.
“I am honored to join the Bright Minds Board as the company transitions from a discovery to a development organization. I look forward to sharing my perspectives and experiences to help Bright Minds advance its innovative clinical and preclinical drug discovery programs,” said David Weiner, MD.
dr Weiner has more than 25 years of experience in the discovery and clinical development of novel therapeutics for neurological, psychiatric and orphan diseases. He began his career at ACADIA Pharmaceuticals, where he held a variety of discovery research and clinical development positions working on several central nervous system (CNS) therapeutics, most notably pimavanserin, a 5-HT2A Receptor inverse agonist approved for the treatment of Parkinson’s psychosis. dr Weiner also served as Chief Medical Officer (CMO) and Interim Chief Executive Officer (CEO) for…
[ad_2]
Source story
